Phase II Study of Liposomal Irinotecan for Advanced Refractory Gastric Cancer

Sponsor
Zhejiang Cancer Hospital
Study ID
NCT06437678
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

To evaluate the objective response rate (ORR) and disease control rate (DCR) of liposomal irinotecan monotherapy in the treatment of recurrent/refractory advanced gastric cancer.

Key Dates

Start date
May 27, 2024
Status verified
May 2024
Primary completion
Feb 28, 2025
Completion
Feb 28, 2026

Study Design

Enrollment
50 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: Recurrent/Refractory Advanced Gastric Cancer

Primary Outcome Measure

Objective response rate (ORR) [ Time Frame: through study completion, an average of 1 year ]

Central Contacts

Related Studies